{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:16:49Z","timestamp":1784233009124,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R21HD103993"],"award-info":[{"award-number":["1R21HD103993"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009824","name":"FSH Society Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["1R21AR080887"],"award-info":[{"award-number":["1R21AR080887"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omtn.2025.102791","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:24:43Z","timestamp":1765239883000},"page":"102791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["DUX4 reduction and muscle function improvement by subcutaneous delivery of gapmer antisense oligonucleotides"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-9916","authenticated-orcid":false,"given":"Aiping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji Rowel Q.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-3546","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5813-1893","authenticated-orcid":false,"given":"Yi-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102791_bib1","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102791_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/22143602241313118","article-title":"Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature","volume":"12","author":"Deenen","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2025.102791_bib3","article-title":"Prevalence and disease progression of genetically-confirmed facioscapulohumeral muscular dystrophy type 1 (FSHD1) in China between 2001 and 2020: a nationwide population-based study","volume":"18","author":"Wang","year":"2022","journal-title":"Lancet Reg. Health West. Pac."},{"key":"10.1016\/j.omtn.2025.102791_bib4","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102791_bib5","doi-asserted-by":"crossref","first-page":"18157","DOI":"10.1073\/pnas.0708659104","article-title":"DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1","volume":"104","author":"Dixit","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102791_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ng1262","article-title":"Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy","volume":"35","author":"van Overveld","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102791_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1086\/302730","article-title":"De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10","volume":"66","author":"van der Maarel","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102791_bib8","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102791_bib9","doi-asserted-by":"crossref","first-page":"e2441","DOI":"10.1212\/WNL.0000000000009617","article-title":"Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy","volume":"94","author":"Hamanaka","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102791_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2025.102791_bib11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/WCO.0b013e328330a572","article-title":"Facioscapulohumeral muscular dystrophy","volume":"22","author":"Padberg","year":"2009","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.omtn.2025.102791_bib12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ng.3844","article-title":"Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL\/HERVL retrotransposons","volume":"49","author":"Hendrickson","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102791_bib13","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.3858","article-title":"DUX-family transcription factors regulate zygotic genome activation in placental mammals","volume":"49","author":"De Iaco","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102791_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151467","article-title":"High Frequency Hearing Loss and Hyperactivity in DUX4 Transgenic Mice","volume":"11","author":"Dandapat","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102791_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw7781","article-title":"A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death","volume":"5","author":"Bosnakovski","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102791_bib16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/mt.2012.68","article-title":"RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy","volume":"20","author":"Wallace","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102791_bib17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102791_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5582\/irdr.2016.01056","article-title":"Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy","volume":"5","author":"Bao","year":"2016","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.omtn.2025.102791_bib19","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2019 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102791_bib20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: A comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2025.102791_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/gt.2011.100","article-title":"Chemical modification and design of anti-miRNA oligonucleotides","volume":"18","author":"Lennox","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2025.102791_bib22","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1007\/s11095-010-0156-0","article-title":"A direct comparison of anti-microRNA oligonucleotide potency","volume":"27","author":"Lennox","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtn.2025.102791_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102791_bib24","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102791_bib25","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/ijms21061952","article-title":"Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2-A Key Single Gene Target for Safe and Effective Inhibition of TGFbeta Signaling","volume":"21","author":"Kuespert","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102791_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089659","article-title":"In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells","volume":"9","author":"Di Martino","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102791_bib27","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1073\/pnas.1909649117","article-title":"Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy","volume":"117","author":"Lim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102791_bib28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ymthe.2020.10.010","article-title":"DUX4 Transcript Knockdown with Antisense 2\u2019-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy","volume":"29","author":"Lim","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102791_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192657","article-title":"A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy","volume":"13","author":"Jones","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102791_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155575","article-title":"Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy","volume":"21","author":"Bittel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102791_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13071040","article-title":"Molecular and Phenotypic Changes in FLExDUX4 Mice","volume":"13","author":"Murphy","year":"2023","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.omtn.2025.102791_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13395-020-00227-4","article-title":"Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity","volume":"10","author":"Jones","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2025.102791_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071623","article-title":"Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression","volume":"10","author":"Lu-Nguyen","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102791_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/hum.2021.251","article-title":"Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM\/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy","volume":"33","author":"Lu-Nguyen","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2025.102791_bib35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/hmg\/ddab136","article-title":"Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model","volume":"30","author":"Lu-Nguyen","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102791_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11092339","article-title":"A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice","volume":"11","author":"Kakimoto","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102791_bib37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.omtn.2021.09.010","article-title":"Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy","volume":"26","author":"Bouwman","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102791_bib38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/biom9080330","article-title":"Cytotoxicity of Dendrimers","volume":"9","author":"Janaszewska","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.omtn.2025.102791_bib39","doi-asserted-by":"crossref","first-page":"9900","DOI":"10.1021\/nn303472r","article-title":"Cationic PAMAM dendrimers aggressively initiate blood clot formation","volume":"6","author":"Jones","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2025.102791_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13395-022-00310-y","article-title":"The double homeodomain protein DUX4c is associated with regenerating muscle fibers and RNA-binding proteins","volume":"13","author":"Claus","year":"2023","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2025.102791_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.802573","article-title":"Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through beta-Catenin in Facioscapulohumeral Muscular Dystrophy","volume":"10","author":"Ganassi","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2025.102791_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13395-017-0148-4","article-title":"Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei","volume":"8","author":"Vanderplanck","year":"2018","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2025.102791_bib43","article-title":"Palmitic Acid Accelerates Endothelial Cell Injury and Cardiovascular Dysfunction via Palmitoylation of PKM2","volume":"12","author":"He","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2025.102791_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70096","article-title":"Protein palmitoylation: biological functions, disease, and therapeutic targets","volume":"6","author":"Qian","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.omtn.2025.102791_bib45","article-title":"Palmitoylation in cardiovascular diseases: Molecular mechanism and therapeutic potential","volume":"58","author":"Wang","year":"2025","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"10.1016\/j.omtn.2025.102791_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.70050","article-title":"A Comparative Analysis of Grip Strength Evaluation Methods in a Large Cohort of Aged Mice","volume":"16","author":"Bigossi","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtn.2025.102791_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/srep42323","article-title":"Modified forelimb grip strength test detects aging-associated physiological decline in skeletal muscle function in male mice","volume":"7","author":"Takeshita","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102791_bib48","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.celrep.2018.10.077","article-title":"AMPK Activation Regulates LTBP4-Dependent TGF-beta1 Secretion by Pro-inflammatory Macrophages and Controls Fibrosis in Duchenne Muscular Dystrophy","volume":"25","author":"Juban","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102791_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1119888","article-title":"Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy","volume":"14","author":"Boccanegra","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102791_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.2213","article-title":"T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid\/mdx mouse","volume":"213","author":"Farini","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.omtn.2025.102791_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0960-8966(98)00093-5","article-title":"Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies","volume":"9","author":"Bernasconi","year":"1999","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2025.102791_bib52","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.234948","article-title":"TNAP limits TGF-beta-dependent cardiac and skeletal muscle fibrosis by inactivating the SMAD2\/3 transcription factors","volume":"132","author":"Arno","year":"2019","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102791_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.matbio.2019.09.003","article-title":"Role of hypoxia in skeletal muscle fibrosis: Synergism between hypoxia and TGF-beta signaling upregulates CCN2\/CTGF expression specifically in muscle fibers","volume":"87","author":"Valle-Tenney","year":"2020","journal-title":"Matrix Biol."},{"key":"10.1016\/j.omtn.2025.102791_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.omtn.2017.11.004","article-title":"A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides","volume":"10","author":"Dieckmann","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102791_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102791_bib56","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102791_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/nat.2015.0576","article-title":"Development of a Method for Profiling Protein Interactions with LNA-Modified Antisense Oligonucleotides Using Protein Microarrays","volume":"26","author":"Kakiuchi-Kiyota","year":"2016","journal-title":"Nucleic Acid Ther."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:00:32Z","timestamp":1784232032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162253125003452"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102791","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DUX4 reduction and muscle function improvement by subcutaneous delivery of gapmer antisense oligonucleotides","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102791"}}